Abbott plans $500 million investment in Chicagoland and Dallas, including up to 300 jobs
- Abbott Laboratories reported a 4% revenue increase to $10.36 billion, just missing analyst expectations of $10.4 billion, according to LSEG estimates.
- Adjusted earnings per share rose 11.2% to $1.09, exceeding expectations by 2 cents, as shown by LSEG data.
- CEO Robert Ford stated, "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."
- Abbott's increased investments of $0.5 billion in Illinois and Texas are expected to go live by the end of 2025.
18 Articles
18 Articles
Abbott Laboratories Dips As Sales Come In Light Despite Profit Beat
Abbott stock slipped early Wednesday after the health giant reported light first-quarter sales, though profit beat expectations. The post Abbott Laboratories Dips As Sales Come In Light Despite Profit Beat appeared first on Investor's Business Daily.

Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance
First-quarter GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or 8.3 percent when excluding COVID-19 testing-related sales1Reported gross margin of 52.8 percent of sales; adjusted gross…
Coverage Details
Bias Distribution
- 71% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage